These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 6331295)

  • 41. In vitro activity of imipenem--a review.
    Braveny I
    Eur J Clin Microbiol; 1984 Oct; 3(5):456-62. PubMed ID: 6389125
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro activity of enoxacin compared with norfloxacin and amikacin.
    van der Auwera P; de Moor G; Lacroix G; Mambour A; Rossion N; Schuyteneer F
    Eur J Clin Microbiol; 1985 Feb; 4(1):55-8. PubMed ID: 3157568
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative activity of CGP 31608, nafcillin, cefamandole, imipenem, and vancomycin against methicillin-susceptible and methicillin-resistant staphylococci.
    Sachdeva M; Hackbarth C; Stella FB; Chambers HF
    Antimicrob Agents Chemother; 1987 Oct; 31(10):1549-52. PubMed ID: 3481245
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The in vitro antibacterial activity of cefozopran against clinically isolated bacteria].
    Higurashi Y; Okuzumi K; Yoneyama A; Nakahara K
    Jpn J Antibiot; 1997 Dec; 50(12):907-16. PubMed ID: 9545668
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Curing of plasmid pE194 with novobiocin and coumermycin A1 in Bacillus subtilis and Staphylococcus aureus.
    Gadó I; Tóth I; Szvoboda G
    Zentralbl Bakteriol Mikrobiol Hyg A; 1987 Jun; 265(1-2):136-45. PubMed ID: 2823505
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In-vitro activity of newer quinolones against aerobic bacteria.
    Auckenthaler R; Michéa-Hamzehpour M; Pechère JC
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative in vitro activity of a new fluorinated 4-quinolone, QA-241.
    Niu WW; Neu HC
    Diagn Microbiol Infect Dis; 1989; 12(3):243-51. PubMed ID: 2791486
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synergism of coumarins from the Chinese drug Zanthoxylum nitidum with antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA).
    Zuo GY; Wang CJ; Han J; Li YQ; Wang GC
    Phytomedicine; 2016 Dec; 23(14):1814-1820. PubMed ID: 27912884
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1994)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Matsuda M; Tanimoto H; Nakata K; Nakamori Y; Kusano N
    Jpn J Antibiot; 1996 May; 49(5):419-55. PubMed ID: 8752860
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro activity of Ro 23-9424, a dual-action cephalosporin, compared with activities of other antibiotics.
    Gu JW; Neu HC
    Antimicrob Agents Chemother; 1990 Feb; 34(2):189-95. PubMed ID: 2327765
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro activity of cefdinir (FK 482, PD 134393, CI-983): a new orally active cephalosporin.
    Qadri SM; Ueno Y; Saldin H; Cunha BA
    Chemotherapy; 1993; 39(2):112-9. PubMed ID: 8458243
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative in vitro activity of LY146032 (daptomycin) against gram-positive cocci.
    Machka K; Braveny I
    Eur J Clin Microbiol; 1987 Feb; 6(1):96-9. PubMed ID: 3032613
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1992)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Tanimoto H; Nakata K; Nakamori Y; Nakatani T; Kusano N
    Jpn J Antibiot; 1996 Jan; 49(1):34-70. PubMed ID: 8851305
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Susceptibility of Campylobacter species to nalidixic acid, enoxacin, and other DNA gyrase inhibitors.
    Taylor DE; Ng LK; Lior H
    Antimicrob Agents Chemother; 1985 Nov; 28(5):708-10. PubMed ID: 3004325
    [TBL] [Abstract][Full Text] [Related]  

  • 55. GyrB mutations in Staphylococcus aureus strains resistant to cyclothialidine, coumermycin, and novobiocin.
    Stieger M; Angehrn P; Wohlgensinger B; Gmünder H
    Antimicrob Agents Chemother; 1996 Apr; 40(4):1060-2. PubMed ID: 8849232
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synergistic interaction between ofloxacin and cefotaxime against common clinical pathogens.
    Jenkins SG; Lewis JW
    Infection; 1995; 23(3):154-61. PubMed ID: 7499004
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative in vitro activity of CGP 31608, a new penem antibiotic.
    Eliopoulos GM; Wennersten C; Reiszner E; Moellering RC
    Antimicrob Agents Chemother; 1987 Aug; 31(8):1188-93. PubMed ID: 3498437
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In-vitro antimicrobial activity of enoxacin in combination with eight other antibiotics against Pseudomonas aeruginosa, Enterobacteriaceae and Staphylococcus aureus.
    Baltch AL; Bassey C; Fanciullo G; Smith RP
    J Antimicrob Chemother; 1987 Jan; 19(1):45-8. PubMed ID: 3104277
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR; Yim J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
    Bassey CM; Baltch AL; Smith RP
    J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.